It’s that time of year again – the time when sell-side junior analysts say goodbye to primetime television and social lives, the time when buy-side analysts hope that they’ll pass through with no smoking craters in their portfolios, and the time when painfully repetitious hold music starts carving away at the sanity of investors and analysts alike. In short, it’s time for earnings from the med-tech sector.
Kicking off with some of the largest names